The FDA's Pharmacy Compounding Advisory Committee has been slated for an upcoming discussion on whether certain peptides from compounding pharmacies should be cleared for use, signaling a potential reversal of a 2023 decision by the agency, as Fierce Pharma reports
Key Takeaways Cagrilintide is a long-acting amylin analogue typically dosed at 2.4 mg weekly in clinical trials, working through distinct pathways from GLP-1 receptor agonists Tirzepatide follows a gradual escalation protocol from 2.5 mg to 15 mg weekly as a dual GIP/GLP-1 receptor agonist No approved combination of cagrilintide with tirzepatide currently exists, though the concept represents theoretical triple-pathway metabolic modulation Gastrointestinal side effects require careful monitoring when considering any combination of these peptides due to overlapping mechanisms Clinical evidence for cagrilintide combinations exists primarily with semaglutide, showing 15-17% body weight reductions in phase 3 trials Understanding Cagrilintide: The Amylin Analogue Cagrilintide represents a breakthrough in amylin-based therapeutics, developed by Novo Nordisk as a long-acting analogue of the naturally occurring hormone amylin[1]
%20eight%20years%20after%20gastric%20bypass%20surgery%3F)
Prescriptions must come from a licensed USA physician: A valid prescription written in English by a primary care physician or licensed medical doctor practicing in the USA is required
doi: 10.2217/clp.12.40 [DOI] [Google Scholar] 72
Join Michelle at our Clinical Evidence Course Auckland | 23 May 2026 | NZD $1,025 +GST #ClinicalEvidence #MedicalEducation #MedicalAffairs #MarketAccess #LifeSciences #HealthTech #MedTech #ProfessionalDevelopment To view or add a comment, sign in Day - 7 Phase I Clinical Trial Definition First-in-human study Also called: Human Pharmacology Phase MTD (Maximum Tolerable Dose) Phase Study Design Can be: Single-centre / Multi-centre Single-national / Multi-national Subjects Conducted on healthy volunteers (stable physiology) Sample Size 20 100 subjects Objectives 1 Primary Endpoint To determine MTD (Maximum Tolerable Dose) Highest dose tolerated without serious adverse events (SAEs) 2 Secondary Endpoint Study: Pharmacokinetics (PK) Pharmacodynamics (PD) MTD (Maximum Tolerable Dose) Definition Maximum dose of drug that is well tolerated without significant side effects Determination Methods SAD (Single Ascending Dose) MAD (Multiple Ascending Dose) Important Conditions Conducted in in-patient setting Subjects monitored 247 for safety Observe for adverse events (AEs) To view or add a comment, sign in Excited to announce our latest publication in Bentham Science - Medicinal Chemistry "Identification of Novel and Selective COX-2 Inhibitors: Comprehensive In-Silico Investigations" Chronic inflammation underlies some of the most debilitating conditions we face today including arthritis, cancer, cardiovascular disease
Potential Side Effects In most cases, supplementing L-carnitine into the diet of healthy dogs is unnecessary, although many pet owners choose to take a preventative approach and give their dogs small amounts regardless
